Quantitation of inhibition of DNA methylation of the retinoic acid receptor β gene by 5-aza-2'-deoxycytidine in tumor cells using a single- nucleotide primer extension assay

Analytical Biochemistry

Volumn 281, Issue 1, 2000, Pages 55-61

  Bovenzi, Veronica ^a   Momparler, Richard L ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

5 Aza 2' deoxycytidine; DNA methylation; Retinoic acid receptor ; Tumor suppressor genes

Indexed keywords

ALKYLATION; CELL CULTURE; DNA; GENES; METHYLATION; NUCLEOTIDES; TUMORS;

5-AZA- 2'-DEOXYCYTIDINE; BREAST CARCINOMA CELLS; DNA METHYLATION; RETINOIC ACID RECEPTORS; SINGLE NUCLEOTIDES; SPECIFIC INHIBITORS; THERAPEUTIC EFFICACY; TUMOR SUPPRESSOR GENES;

POLYMERASE CHAIN REACTION;

5 AZA 2' DEOXYCYTIDINE; 5 METHYLCYTOSINE; RETINOIC ACID RECEPTOR;

ARTICLE; BINDING SITE; BREAST CANCER; COLON CANCER; DNA METHYLATION; DRUG EFFICACY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE DIAGNOSIS; RECEPTOR GENE; REPRODUCIBILITY; SILENCER GENE; TUMOR SUPPRESSOR GENE;

EID: 0034658653     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1006/abio.2000.4562     Document Type: Article

References (29)

1. Jones P. A., Laird P. W. Cancer epigenetics comes of age. Nature Genet. 21:1999;163-167.
2. Merlo A., Herman J. G., Mao L., Gabrielson E., Burger P. C., Baylin S. B., Sidransky D. 5′ CpG islands methylation is associated with transcriptional silencing of the tumor suppressor gene p16/CDKN2/MTS1 in human cancers. Nat. Med. 1:1995;686-692.
3. Herman J. G., Latif F., Weng Y., Lerman M. I., Zbar B., Liu S., Samid D., Duan D. S., Gnarra J. R., Linehan W. M. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA. 91:1994;9700-9704.
4. Greger V., Debus N., Lohmann D., Hopping W., Passarge E., Horsthemke B. Frequency and parental origin of hypermethylated Rb1 alleles in retinoblastoma. Hum. Genet. 94:1994;491-496.
5. INK4B1. Cancer Res. 56:1996;722-727.
6. Kane M. F., Loda M., Gaida G. M., Lipman J., Mishra R., Goldman H., Jessup J. M., Kolodner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cells lines. Cancer Res. 57:1997;8098-8110.
7. Yoshiura K., Kanai Y., Ochiai A., Shimoyama Y., Sugimura T., Hirohashi S. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc. Natl. Acad. Sci. USA. 92:1995;7416-7419.
8. Graff J. R., Greenberg V. E., Herman J. G., Westra W. H., Boghaert E. R., Ain K. B., Saji M., Zeiger M. A., Zimmer S. G., Baylin S. B. Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurle's cell, and poorly differentiated human thyroid carcinoma. Cancer Res. 58:1998;2063-2066.
9. Ahuja N., Mohan A. L., Li Q., Stolker J. M., Herman J. G., Hamilton S. R., Baylin S. B., Issa J.-P. J. Association between CpG islands methylation and microsatellite instability in colorectal cancer. Cancer Res. 57:1997;3370-3374.
10. Rivard G. E., Momparler R. L., Demers J., Benoit P., Raymond R., Lin K. T., Momparler L. F. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leukemia Res. 5:1981;453-462.
11. Momparler R. L., Rivard G. E., Gyger M. Clinical trial on 5-aza-2′-deoxycytidine in patients with acute myeloid leukemia. Pharmacol. Ther. 30:1985;277-286.
12. Petti M. C., Mandelli F., Zagonel V., Gregoris C. D., Merola M. C., Latagliata R., Gattei V. P., Fazi P., Monfardini S., Pinto A. Pilot study of 5-aza-2′-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: Preliminary results. Leukemia. 7:1993;36-41.
13. Momparler R. L., Bouffard D. Y., Momparler L. F., Dionne J., Belanger K., Ayoub J. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs. 8:1997;358-368.
14. Kuppuswamy M. N., Hoffmann J. W., Kasper C. K., Spitzer S. G., Groce S. L., Bajaj S. P. Single nucleotide primer extension to detect genetic diseases: Experimental application to hemophilia B (factor IX) and cystic fibrosis genes. Proc. Natl. Acad. Sci. USA. 88:1991;1143-1147.
15. Gonzalgo M. L., Jones P. A. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res. 25:1997;2529-2531.
16. Bender C. M., Pao M. M., Jones P. A. Inhibition of DNA methylation by 5-Aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 58:1998;95-101.
17. Caliaro M. J., Marmouget C., Guichard S., Mazars P., Vallette A., Moisand A., Bugat R., Jozan S. Response of four ovarian carcinoma cell lines to all-trans retinoic acid: Relationship with induction of differentiation and retinoic acid receptor expression. Int. J. Cancer. 56:1994;743-748.
18. Houle B., Rochette-Egly C., Bradley W. E. C. Tumor-suppressive effect of retinoic acid receptor β in human epidermoid lung cancer cells. Proc. Natl. Acad. Sci. USA. 90:1993;985-989.
19. Bovenzi V., Le N. L. O., Côté S., Sinnett D., Momparler L. F., Momparler R. L. DNA methylation of retinoic acid receptor β in breast cancer and possible therapeutic role of 5-aza-2′-deoxycytidine. Anticancer Drugs. 10:1999;471-476.
20. Côté S., Sinnett D., Momparler R. L. Demethylation by 5-aza-2′-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor β gene in human colon carcinoma cells. Anticancer Drugs. 9:1998;743-750.
21. Li Y., Mitaxov V., Waxman G. Structure-based design of Taq DNA polymerase with improved properties of dideoxynucleotide incorporation. Proc. Natl. Acad. Sci. USA. 96:1999;9491-9496.
22. Frommer M., McDonald L. E., Millar D. S., Collins C. M., Watt F., Grigg G. W., Molloy P. L., Paul C. L. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl. Acad. Sci. USA. 89:1992;1827-1831.
23. Herman J. G., Graff J. R., Myohanen S., Nelkin B. D., Baylin S. B. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA. 93:1996;9821-9826.
24. INK4 protein induction by 5-Aza-2′-deoxycytidine. Oncogene. 11:1995;1211-1216.
25. Graff J. R., Herman J. G., Lapidus R. L., Chopra H., Xu R., Jarrard D. F., Isaacs W. B., Pitha P. M., Davidson N. E., Baylin S. B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 55:1995;5195-5199.
26. Ferguson A. T., Lapidus R. G., Baylin S. B., Davidson N. E. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res. 55:1995;2279-2283.
27. Harrison J., Stirzaker C., Clark S. Cytosine adjacent to methylated CpG sites can be partially resistant to conversion in genomic bisulfite sequencing leading to methylation artifacts. Anal. Biochem. 264:1998;129-132.
28. Warnecke P. M., Stirzaker C., Melki J. R., Millar D. S., Paul C. L., Clark S. J. Detection and measurement of PCR bias in quantitative methylation analysis of bisulphite-treated DNA. Nucleic Acids Res. 25:1997;4422-4426.
29. Bouffard D. Y., Laliberté J., Momparler R. L. Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem. Pharmacol. 45:1993;1857-1861.